Phasix ST Parastomal Hernia Mesh
Davol, Inc., A Subsidiary of C.R. Bard, Inc. · Decision date Sep 28, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on September 28, 2026 for Phasix ST Parastomal Hernia Mesh, submitted by Davol, Inc., a subsidiary of C.R. Bard, Inc., under K261543. The device is a sterile, single-use, prescription-only surgical mesh of bioabsorbable poly-4-hydroxybutyrate co-knitted with polyglycolic acid fibers, coated on the PGA surface with an absorbable HA/CMC/PEG hydrogel; the submission states the mesh materials are identical in composition to the reference device, Phasix ST Mesh (K143380). The listed predicate is BioDesign Parastomal Hernia Repair Graft (K162934).
The stated indication is reinforcement of soft tissue where weakness exists in procedures for repair of parastomal hernias. The clearance covers the device as described in the 510(k) summary; it is not a PMA approval. The summary does not provide clinical outcome data, and the source does not state a review of long-term performance in patients, so any such assessment remains unknown.
The record lists regulation 21 CFR 878.3300, Class II, product codes OWT, OOD and FTL, with a General and Plastic Surgery specialty; the application was received May 8, 2026.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 28, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261543
- Regulatory pathway
- 510(k) premarket notification
- Product code
- OWT
- Decision code
- SESE
- Decision date
- Sep 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Mesh, Surgical, Absorbable, Abdominal Hernia.
- Product code
- OWT
- FDA device class
- 2
FDA decision timeline
K261543 received
Application receipt date recorded by FDA.
K261543 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code OWT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Sofradim Production | 510(k) clearance | Oct 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Davol, Inc., A Subsidiary of C.R. Bard, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Warwick, RI
Sources and methodology
- Original FDA record: K261543
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records